Nanoscope Presented Positive Trial Results for Retinitis Pigmentosa
Nanoscope Therapeutics, Inc., a biotechnology company in the BLA filing stage focused on gene therapies for retinal degenerative diseases, announced promising 2-year results from the Phase 2b RESTORE randomized, controlled clinical trial (RCT) of its leading program, MCO-010. This mutation-agnostic gene therapy targets patients with permanent, severe vision loss due to advanced retinitis pigmentosa (RP). The results were presented by Dr. Allen C. Ho, MD, FACS, FASRS, Director of Retina Research and Co-Director of the Retina Service at Wills Eye Hospital, and Chief Medical Advisor at Nanoscope. RESTORE is the first RCT to demonstrate statistically significant visual acuity improvements in RP patients and will play a pivotal role in the forthcoming BLA submission for Nanoscope’s RP program.
Nanoscope Presented Positive Trial Results for Retinitis Pigmentosa